Jackson Creek Investment Advisors LLC Purchases Shares of 103,592 Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Jackson Creek Investment Advisors LLC bought a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 103,592 shares of the company's stock, valued at approximately $1,313,000. Jackson Creek Investment Advisors LLC owned 0.10% of Day One Biopharmaceuticals as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. First Turn Management LLC purchased a new stake in Day One Biopharmaceuticals in the 3rd quarter worth approximately $13,204,000. GSA Capital Partners LLP acquired a new stake in Day One Biopharmaceuticals during the third quarter valued at $825,000. Algert Global LLC increased its holdings in Day One Biopharmaceuticals by 248.8% in the third quarter. Algert Global LLC now owns 71,487 shares of the company's stock valued at $996,000 after buying an additional 50,990 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Day One Biopharmaceuticals in the fourth quarter worth about $866,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Day One Biopharmaceuticals by 14.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company's stock worth $7,069,000 after acquiring an additional 64,700 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

Day One Biopharmaceuticals Stock Performance

Shares of Day One Biopharmaceuticals stock traded up $0.59 on Tuesday, reaching $8.66. The company had a trading volume of 1,685,642 shares, compared to its average volume of 1,227,625. The firm's 50 day moving average price is $11.68 and its two-hundred day moving average price is $13.15. Day One Biopharmaceuticals, Inc. has a 52-week low of $7.88 and a 52-week high of $18.07. The firm has a market cap of $877.73 million, a PE ratio of -8.41 and a beta of -1.38.

Remove Ads

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. As a group, sell-side analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 12,048 shares of Day One Biopharmaceuticals stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the completion of the transaction, the chief executive officer now directly owns 128,015 shares of the company's stock, valued at $1,531,059.40. The trade was a 8.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Adam Dubow sold 4,646 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,064 shares of company stock worth $251,925. 8.40% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DAWN shares. Needham & Company LLC restated a "buy" rating and issued a $32.00 price target on shares of Day One Biopharmaceuticals in a research note on Wednesday, February 26th. JPMorgan Chase & Co. cut their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a research note on Wednesday, March 5th. HC Wainwright decreased their price target on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group cut their price objective on Day One Biopharmaceuticals from $48.00 to $43.00 and set a "buy" rating for the company in a research note on Monday, February 10th. Finally, Wedbush restated an "outperform" rating and issued a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $34.57.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.